Phaseline

Companies › Cabaletta Bio

Cabaletta Bio: clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 4 Phase 1, 2 Phase 2; Immunology, Neurology; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CABA-201
CD19-specific chimeric antigen receptor T cells
CD19Phase 2Idiopathic Inflammatory Myopathy; Systemic Sclerosis; Pemphigus Vulgaris; Generalized Myasthenia Gravis (gMG) …Jul 2028
DSG3-CAART
Desmoglein 3 chimeric autoantibody receptor T cells
DSG3Phase 1Pemphigus VulgarisJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06154252CABA-201Phase 2Idiopathic Inflammatory MyopathyImmunologyJul 2028
NCT04422912CABA-201Phase 1Pemphigus VulgarisImmunologyJan 2029
NCT04422912DSG3-CAARTPhase 1Pemphigus VulgarisImmunologyJan 2029
NCT06328777CABA-201Phase 2Systemic SclerosisImmunologyJul 2029
NCT06359041CABA-201Phase 1Generalized Myasthenia Gravis (gMG)NeurologySep 2029
NCT06121297CABA-201Phase 1Systemic Lupus ErythematosusImmunologyDec 2029

From the company's SEC filings

Cash and short-term investments of $299m on 2026-09-30; operating cash outflow about $170m a year; runway about 21 months at that burn, to Jul 2028; 0 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CD19 (1) DSG3 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Companies built like this

Edesa Biotech Kyverna Therapeutics Abeona Therapeutics Anterogen VivaTech International

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.